| 
| Need Turn-Key Microbiome Analysis Services? Utilize streamlined and validated direct-to-consumer microbiome testing workflows. You can economize time and resources working with industry expert scientists. See how Zymo Research’s customizable Microbiome Sequencing Services can help you. Learn More. |
- The top 10 biotech IPOs of 2021
- Moderna's RSV shot sails on to phase 3, tightening Big Pharma battle royale
- Takeda's gene therapy ambitions rise another $2B in 4-program Code Bio pact
- Sponsored: Recommended Strategies for Your Next Biomarker-Driven Clinical Trial
- BioNTech jumps into PRAME game, paying Medigene $29M for preclinical T-cell therapy program
- Synairgen's pivotal COVID-19 SPRINTER trial falls at final hurdle, sending stock into downward spiral
- Biotech IPOs in the current market environment? Experts say it's 'a bit silly, if not suicidal'
- Adagio CEO resigns with no explanation and the biotech plans COVID-19 antibody analysis this quarter
- Building off Prevail buy, Lilly to construct $700 million Boston research hub in gene therapy blitz
- The top 10 medtech IPOs of 2021
- AstraZeneca, Daiichi target broad breast cancer use with Enhertu's landmark win in HER2-low disease
- Medtronic's earnings flatten out as COVID pandemic, healthcare worker shortage rage on
- GlaxoSmithKline unveils Haleon, the new brand name for its outgoing consumer health unit
- Payers, Medicaid officials ask Congress for 120-day glide path to end of COVID-19 emergency
- Skin fibroblasts play role in acne formation in human samples and mice, researchers find
Featured Story | By Annalee Armstrong The IPO market started off blazing hot in 2021, but valuations and interest began to cool toward the end of the year. We still saw a record-breaking 100 listings, with more and more companies filing for the public markets before producing even a shred of data. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Moderna’s RSV vaccine candidate is heading for phase 3 after an independent safety review cleared the shot to advance. The decision is based on data from a phase 2 trial, called ConquerRSV, which found the vaccine to be safe and tolerable at the selected dose. read more By Kyle LaHucik Takeda has signed up for yet another multibillion-dollar gene therapy pact, this time encoding a $2 billion biobucks deal with little-known Code Biotherapeutics across four programs. read more Sponsored by: Precision for Medicine The use of biomarkers to individualize treatment is a cornerstone of precision medicine. Successful incorporation of biomarkers for effective patient identification and selection requires careful planning. Learn about Precision's recommended strategies for overcoming 4 common challenges in biomarker-driven trials. read more By Nick Paul Taylor BioNTech, flush with COVID-19 cash, has struck another deal. The latest agreement will see the German biotech pay 26 million euros ($29 million) for a preclinical T-cell receptor program from its compatriot Medigene. read more By Nick Paul Taylor Synairgen’s time riding the COVID-19 wave has come crashing to a close. Its inhaled interferon beta candidate SNG001 posted a clean sweep of failures against key endpoints in a phase 3 clinical trial of hospitalized COVID-19 patients, prompting investors to flee despite Synairgen’s search for a silver lining. read more By Kyle LaHucik 2021 saw a rush of biotechs heading for the public markets, including companies seeking an initial public offering before ever producing a shred of clinical evidence. And they paid for it. read more By Kyle LaHucik Adagio CEO Tillman Gerngross, Ph.D., resigned last week with no public explanation, and the biotech replaced him with Chief Operating Officer David Hering, who led Pfizer's mRNA unit. The biotech said it plans to analyze phase 2/3 data of its COVID-19 antibody, for both prevention and treatment, before March 31. read more By Max Bayer More than a year after acquiring gene therapy-focused biotech Prevail Therapeutics, Eli Lilly is doubling down, investing $700 million in a new research hub in Boston slated to expand the Indianapolis-based pharma's portfolio of gene therapies. read more By Conor Hale The second year of the COVID-19 pandemic saw a wave of global demand for coronavirus tests and telehealth that finally reached the public markets. But all waves ebb and flow, and many companies may have seen their stock value crest early in 2021. read more By Angus Liu AstraZeneca and Daiichi Sankyo’s Enhertu could unlock another blockbuster market thanks to a new trial win in breast cancer with low HER2 expression, which affects a much larger population than the drug’s existing HER2-positive indication. read more By Andrea Park For the latest quarter, Medtronic raked in $7.76 billion, about 1% lower than the previous quarter’s haul and 0.2% below its earnings for the same period in 2021. read more By Angus Liu CEO, check. Chairman, check. A new headquarters, being planned. And GlaxoSmithKline now has a new name for its consumer health unit. read more By Robert King A group of payers and state Medicaid officials want a 120-day notice from Congress when the COVID-19 public health emergency will end, warning that the redeterminations of Medicaid eligibility will be a massive operational challenge. read more By Kyle LaHucik Skin fibroblasts play a role in the build up of acne, researchers said, pointing to new insights on how the skin condition forms at a molecular level. The researchers also found that the common acne prescription retinoic acid might target fibroblasts in skin, highlighting a reason for its effectiveness in treating acne. read more Resources Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Blue Matter What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Fierce Drug Safety Summit March 8-9, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Health IT Summit May 24, 2022 | Virtual Event Fierce Leaders in Life Sciences Forum May 24, 2022 | Complimentary Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next-Gen Week June 29-30, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Fierce Biotech Summit September 13-14, 2022 | Boston, MA Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit (MASS West) September 2022 | San Diego, CA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce European Trial Master File Summit October 31- November 2, 2022 | London Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce New Product Planning Summit November 30 - December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 1, 2023 | 
